These results confirm that, despite being used less and less worldwide, DES (drug eluting stents) are the best option in saphenous vein grafts. Saphenous vein graft atherosclerosis has a different pathophysiology to that of native arteries, and PCI in this context is less effective because of high risk of friable thromboembolic material, faster plaque<a href="https://solaci.org/en/2016/09/07/des-best-option-in-saphenous-vein-grafts/" title="Read more" >...</a>
Original Title: Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the PACUBA trial. Reference: Kinstner CM et al. J Am Coll Cardiol Intv. 2016;9:1386-1392. Patients with symptomatic femoropopliteal in-stent restenosis (ISR) have better patency at one year if treated with drug eluting<a href="https://solaci.org/en/2016/07/13/deb-the-best-option-to-treat-superficial-femoral-isr/" title="Read more" >...</a>
Original Title: Long-Term Results of Everolimus-Eluting Stents versus Drug-Eluting Balloons in Patients with Bare-Metal In-Stent Restenosis 3-Year Follow-Up of the RIBS V Clinical Trial. Reference: Alfonso F. et al. JACC Cardiovasc Interv. 2016 Jun 27;9(12):1246-55. Courtesy of Dr. Agustín Vecchia. RIBS V 3 year follow up Stents have become the gold standard for<a href="https://solaci.org/en/2016/06/28/instent-restenosis-drug-eluting-balloons-or-drug-eluting-stents/" title="Read more" >...</a>
Original Title: Stent Thrombosis with Drug Eluting Stents and Bioresorbable Scaffolds. Evidence from a Network Meta-Analysis of 147 trials. Reference: Kang S et al. J Am Coll Cardiol Intv 2016 doi 10.1016. Courtesy of Dr. Guillermo Migliaro. When treating heart disease, drug eluting stents (DES) have become essential for PCI. Its main advantage lies on<a href="https://solaci.org/en/2016/06/13/stent-thrombosis-comparative-analysis-between-bms-des-and-brs/" title="Read more" >...</a>
Original Title: Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan 12-Month Results. Reference: Hiroyoshi Yokoi et al. J Am Coll Cardiol Intv. 2016;9(3):271-277. This multicenter prospective study carried out in Japan assessed the paclitaxel eluting stent Zilver PTX in an unselected real world population very different to<a href="https://solaci.org/en/2016/05/17/zilver-ptx-maintains-efficacy-in-real-life-most-challenging-lesions/" title="Read more" >...</a>
Original Title: Drug-Coated Balloons for Complex Femoropopliteal Lesions2-Year Results of a Real-World Registry. Reference: Andrej Schmidt et al. J Am CollCardiolIntv. 2016;9(7):715-724. The superiority of drug coated balloons compared to conventional balloons in femoropopliteal lesions have been shown by randomized studies, but only in short and simple lesions. The efficacy of drug coated balloons<a href="https://solaci.org/en/2016/04/14/drug-coated-balloons-in-complex-superficial-femoral-artery-lesions/" title="Read more" >...</a>
Original Title: Percutaneous Transluminal Angioplasty and Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia (PADI) Trial. Reference: Marlon I. Spreen et al. Circ Cardiovasc Interv. 2016 Feb;9(2):e002376. The treatment of infrapopliteal lesions in patients with critical limb ischemia is limited by the high rates of restenosis. The most frequent course of treatment is<a href="https://solaci.org/en/2016/03/08/des-in-critical-ischemia-caused-by-infrapopliteal-lesions/" title="Read more" >...</a>
Original Title: Clopidogrel versus Aspirin as an Antiplatelet Monotherapy after 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents. Reference: Taek Kyu Park et al. Circ Cardiovasc Interv. 2016 Jan;9(1):e002816. Courtesy of Dr. José Amadeo Guillermo Álvarez. The use of dual antiplatelet therapy (DAPT) over 12 months after hospitalization for acute myocardial infarction (AMI) or drug<a href="https://solaci.org/en/2016/02/04/aspirin-or-clopidogrel-as-monotherapy-after-12-month-dapt/" title="Read more" >...</a>
Original Title: Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial CME. Reference: Ricardo A. Costa et al. J Am Coll Cardiol Intv. 2016;9(1):51-64. The purpose of this study was to assess the efficacy and long<a href="https://solaci.org/en/2016/01/26/polymer-free-biolimus-coated-stent-5-year-outcomes/" title="Read more" >...</a>
Original Title: Sustained Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions. 24-Month Results of IN.PACT SFA. Reference: John R. Laird et al. J Am CollCardiol. 2015 [Epub ahead of print]. The IN.PACT SFA studies and follows up patients treated with IN.PACT Admiral DCB (Medtronic®) for superficial femoral artery (SFA) and popliteal artery disease.<a href="https://solaci.org/en/2015/11/29/sustained-benefit-of-treatment-with-drug-coated-balloon-for-femoropopliteal-lesions-in-pact-sfa-results-at-24-months/" title="Read more" >...</a>